Hamanishi et al suggested that PD-L1 may directly suppress antitumor CD8-positive T cells in ovarian cancer, making the PD-1/PD-L1 pathway an important target for restoring antitumor immunity [46]. This evidence concerns the gene PDCD1 and ovarian carcinoma.